Ellis Fischel Cancer Center
Print    Email
Decrease (-) Restore Default Increase (+) font size
Referring Providers
Clinical Trials at Ellis Fischel
Log In to View Record
Online Access FAQ
Referring Providers Online Support
Physician Support Services
Find A Clinic
Find a Physician
UPdate Newsletter
Clinical Trials at Ellis Fischel

Clinical Trials at Ellis Fischel Cancer Center: (573) 882-7440

What are clinical trials?
Clinical trials are reserach studies that involve people. They are the final step in a long process that begins with research in a lab and animal testing.  Many treatments used today are the result of past clinical trials.

In cancer, clinical trials are designed to answer questions about new ways to:

  • Treat Cancer
  • Find and diagnose cancer
  • Prevent cancer
  • Manage symptoms of cancer or side effects from its treatment

Studies are designed to answer questions about new treatments or ways of using an existing treatment better.  These trials test many types of treatments, such as new:

  • Drugs or vaccines
  • Ways to do surgery or give radiation therapy
  • Combinations of treatments

Please visit the following link for more information from the National Cancer Institute (NCI) about Clinical Trials:  http://www.cancer.gov/clinicaltrials/learningabout

Ellis Fischel Cancer Center physicians and staff ensure that all of our patients receive the best care. This means if we ask you or a loved one to participate in a clinical trial, we have good reason to believe thaat the new treatment(s) will help and we see promise and potential in the new treatment options. These new treatments could become the new standard of care and we want only the best for our patients. 

Brain Cancers

• An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma 

Breast Cancer



• A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

• A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer 

• A Phase III, Randomized Clinial Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patinets with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less.

Ductal Carcinoma In Situ

• A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Neo Adjuvant

• A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer


• Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer
**Temporaily Closed for Interim Analysis***

• A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

Gastrointestinal (GI) Cancer


• A Phase III Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab in subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer

• Phase III Randomized Study of Adjuvant FOLFOX Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Celecoxib in Patients With Resected Stage III Colon Cancer


• Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)


• Phase III Randomized Study of Adjuvant Gemcitabine Hydrochloride With Versus Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With Versus Without Chemoradiotherapy With Either Capecitabine or Fluorouracil in Patients With Resected Head of Pancreas Adenocarcinoma 

• Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 ( NSC-749607)  vs Mfolfox  in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy


• A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Genitourinary Cancer


• A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer

• Phase III Trial of Dose Excalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GNRH Agonist and TAK-700 for Men With High Risk Prostate Cancer

• A Phase III Randomized Trail Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer


• A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab To Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma


Gynecological Cancer



• Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy


• Phase III Randomized Study of Adjuvant Chemoradiotherapy Comprising Cisplatin and Tumor Volume-Directed Radiotherapy Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients With Stage I-IVA


• Phase III Randomized Study of PaclitaxelVersus Polyglutamate Paclitaxel as Consolidation/Maintenance Therapy Versus No Further Anticancer Therapy Until Disease Progression in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer or Fallopian Tube Cancer

• Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

• Phase III Randomized Study of Paclitaxel With Carboplatin Versus Ifosfamide in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV Persistent or Recurrent Uterine or Ovarian Carcinosarcoma

• A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian tube or Primary Peritoneal Cancer


Head & Neck Cancer

Locally Advanced

• Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck


• Phase III Randomized Study of Platinum-Containing Chemotherapy With Versus Without Bevacizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

• Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel And Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Lung Cancer

Non-Small Cell Lung Cancer

• Phase III Randomized Study of Sunitinib Malate as Maintenance Therapy in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Combination Chemotherapy (Second Line)

• A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer. (First line, stage III/IV)

• Randomized phase III Study of Maintance Therapy With Bevacizumab, Pemetrexed, or a Combination Of Bevacizumab and Premetrexed, Following CarboplatinPaclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

• Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

Limited-Stage Small Cell Lung Cancer

• Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

• Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination Of Bevacizumab and Pemetrexed Following Carboplatin and Bevacixumab for advanced Non-Squamous NSCLC

Skin Cancer


• A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma

• A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA 4 Therapy Versus High-Dose Interferon α-2b for stage IIIB - IV Resected High-Risk Melanoma 



• Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia 

• A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

• Blood Draw - Inhibitors mevalonate pathways. For patients with newly diagnosed, refractory, progressive, or relapsed CLL, Myeloma, or Leukemia 


• A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma

• Intergroup Randomized Phase II Four Arm Study In Patients Greater Than or Equal to 60 With Previously Untreated Mantle Cell Lymphoma

• Phase II Study of Dose-Ajusted EPOCH +/- Rituximab in Adults with untreated Burkitt Lymphoma, C-Myc positive Diffuse large B Cell Lymphoma and Plasmablastic Lymphoma



Human Resources Giving Disclaimer Notice of Privacy Practices Web Communications Social Media Site Index
Mizzou University of Missouri University of Missouri System